Glucotrack, Inc. (Nasdaq: GCTK) is partnering with OneTwo Analytics AB to analyze clinical study data from its Continuous Blood Glucose Monitor (CBGM) using AI and machine learning. The CBGM is a long-term implantable device that directly measures blood glucose, aiming to provide more accurate, real-time readings compared to traditional interstitial fluid-based monitors. This collaboration seeks to demonstrate the long-term benefits and clinical value of Glucotrack’s novel approach to glucose monitoring.
This partnership holds significant implications for the diabetes management landscape. Implantable, long-term glucose monitors could revolutionize patient care by eliminating the need for frequent finger pricks or sensor replacements. The use of AI-driven analytics further enhances the value proposition by potentially uncovering deeper insights into glucose patterns and individual patient responses, paving the way for more personalized treatment strategies. Validating the accuracy and long-term performance of a direct blood glucose measurement system could significantly disrupt the existing CGM market.
The CBGM offers a unique advantage by measuring glucose directly from the blood, potentially eliminating the lag time associated with interstitial fluid measurements. Designed for three years of continuous use, the implantable device provides a convenient and less intrusive monitoring option. OneTwo Analytics’ expertise in diabetes data analytics and clinical study analysis will be crucial in processing and interpreting the data generated from the ongoing CBGM clinical study. This collaboration will generate actionable clinical dashboards, potentially supporting healthcare providers in making more informed decisions.
This partnership signals a potential shift in the future of diabetes management. The combination of innovative hardware and sophisticated data analysis may not only improve the quality of life for people with diabetes but also contribute to more efficient and effective healthcare delivery. The success of this collaboration could establish a new standard for continuous glucose monitoring and encourage further advancements in diabetes technology.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
